Rabbit Polyclonal SLC20A2/PIT2 antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human SLC20A2 aa 100-450.
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 10% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine
WB | |
---|---|
Human | Tested |
Cat | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500.00000 - 1/3000.00000 | Notes As is commonly seen with membrane proteins, significant hydrophobicity can lead to aggregation following boiling of samples prior to SDS-PAGE and subsequent western blotting. We recommend to avoid boiling in this case. |
Species | Dilution info | Notes |
---|---|---|
Species Cat | Dilution info - | Notes - |
Select an associated product type
Sodium-phosphate symporter which preferentially transports the monovalent form of phosphate with a stoichiometry of two sodium ions per phosphate ion (PubMed:12205090, PubMed:15955065, PubMed:16790504, PubMed:17494632, PubMed:22327515, PubMed:28722801, PubMed:30704756). Plays a critical role in the determination of bone quality and strength by providing phosphate for bone mineralization (By similarity). Required to maintain normal cerebrospinal fluid phosphate levels (By similarity). Mediates phosphate-induced calcification of vascular smooth muscle cells (VCMCs) and can functionally compensate for loss of SLC20A1 in VCMCs (By similarity). (Microbial infection) Functions as a retroviral receptor and confers human cells susceptibility to infection to amphotropic murine leukemia virus (A-MuLV), 10A1 murine leukemia virus (10A1 MLV) and some feline leukemia virus subgroup B (FeLV-B) variants.
GLVR2, PIT2, SLC20A2, Sodium-dependent phosphate transporter 2, Gibbon ape leukemia virus receptor 2, Phosphate transporter 2, Solute carrier family 20 member 2, GLVR-2, PiT-2, Pit2, hPit2
Rabbit Polyclonal SLC20A2/PIT2 antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human SLC20A2 aa 100-450.
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 10% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine
SLC20A2 also known as PIT2 is a sodium-dependent phosphate transporter protein with a molecular mass of approximately 80 kDa. It facilitates the uptake of inorganic phosphate into cells which is critical for various cellular functions. This protein is expressed in many tissues including the brain kidneys and lungs. In the brain SLC20A2 plays an important role in maintaining phosphate homeostasis which is necessary for neuronal activity and development.
The function of this transporter protein is to maintain phosphate balance at the cellular level. It does not form any known complex with other proteins but works by itself to regulate phosphate uptake. SLC20A2 activity is essential for normal bone mineralization and energy metabolism. The phosphate transported by SLC20A2 is used in ATP production and biological signaling processes highlighting its importance in cellular metabolism.
The role of SLC20A2 is particularly evident in the phosphate metabolism pathway. It works alongside other family proteins like SLC20A1 to regulate phosphate levels. Alteration in these pathways can impact cellular processes such as glycolysis and oxidative phosphorylation emphasizing the need for precise phosphate balance. SLC20A2 interacts with various signaling pathways that control cellular growth and differentiation showing its significance in energy and phosphate-related pathways.
Abnormal SLC20A2 function has been linked to idiopathic basal ganglia calcification a disorder characterized by calcium deposit in brain regions affecting motor control. Mutations in the SLC20A2 gene can disrupt phosphate transport leading to abnormal calcium accumulation. This disorder often involves other proteins such as XPR1 which can also be implicated in phosphate transport. Understanding the role of SLC20A2 in this context helps in developing targeted therapies for better disease management.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-SLC20A2/PIT2 antibody (ab155259) at 1/500 dilution
All lanes: Unboiled U87-MG cell lysate at 30 µg
Predicted band size: 70 kDa
All lanes: Western blot - Anti-SLC20A2/PIT2 antibody (ab155259) at 1/500 dilution
Lane 1: A431 whole cell extracts
Lane 2: Unboiled A431 whole cell extracts
Predicted band size: 70 kDa
7.5% SDS PAGE
All lanes: Western blot - Anti-SLC20A2/PIT2 antibody (ab155259) at 1/500 dilution
All lanes: 293T whole cell lysate at 30 µg
Predicted band size: 70 kDa
Image collected and cropped by CiteAb under a CC-BY license from the publication
SLC20A2/PIT2 western blot using anti-SLC20A2/PIT2 antibody ab155259. Publication image and figure legend from Castella, B., Kopecka, J., et al., 2017, Nat Commun, PubMed 28580927.
ab155259 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab155259 please see the product overview.
ZA treatment does not affect other transporters in ZA and SIM-treated DC.Levels of the indicated plasma-membrane-associated proteins are evaluated by western blot in biotinylated extracts from untreated or 1 μM ZA and/or simvastatin (SIM) treated DC. Pancadherin is employed as a control of equal protein loading. The blots are representative of one out of the three experiments. (b) Activities of the indicated plasma-membrane-associated proteins are measured after immunopurification from the biotinylated extracts of DC treated, as shown in a. The results are expressed as nmoles hydrolysed phosphate (Pi)/min/mg proteins according to the previously prepared titration curve. The NHE1 activities and SLC4A1 activities are fluorimetrically measured, and the results are expressed as ΔpHi/min and arbitrary units, respectively. The bars represent the mean±s.e.m. of three experiments. None of the differences is statistically significant.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com